↓ Skip to main content
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

patent
2 patents

Readers on

mendeley
33 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group
Published in
Investigational New Drugs, June 2014
DOI 10.1007/s10637-014-0111-8
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
France 1 3%
Unknown 32 97%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 7 21%
Student > Master 3 9%
Student > Postgraduate 3 9%
Other 2 6%
Student > Bachelor 2 6%
Other 5 15%
Unknown 11 33%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 10 30%
Biochemistry, Genetics and Molecular Biology 3 9%
Nursing and Health Professions 2 6%
Agricultural and Biological Sciences 2 6%
Veterinary Science and Veterinary Medicine 1 3%
Other 3 9%
Unknown 12 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2025.
All research outputs
#10,072,560
of 29,319,267 outputs
Outputs from Investigational New Drugs
#454
of 1,369 outputs
Outputs of similar age
#86,757
of 248,659 outputs
Outputs of similar age from Investigational New Drugs
#9
of 18 outputs
Altmetric has tracked 29,319,267 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,369 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,659 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.